Principal investigator:Rury Holman
The Fasting Hyperglycaemia Study (FHS) was a six-year, prospective, randomised, placebo-controlled study in subjects who had two consecutive fasting plasma glucose levels in the range 5.5 to 7.7 mmol/L and were thought to be at risk of developing diabetes. The primary aim of the trial was to determine whether deterioration in glycaemic tolerance towards diabetes can be delayed or prevented using an insulin secretagogue (sulphonylurea) or reinforced healthy living advice.
The results of the FHS trial where presented at the EASD meeting in Jerusalem.
Randomised controlled trial of sulphonylurea therapy for subjects with increased fasting glucose levels
FHS group, Karunakaran S, Hammersley MS, Morris RJ, Turner RC, Holman RR
Metabolism 1997;46:56-60
Randomised controlled trial of enforced healthy-living advice in subjects with increased but not diabetic fasting glucose
Fasting hyperglycaemia Study Group, Dyson PA, Hammersley MS, Morris RJ, Holman RR, Turner RC
Metabolism 1997;46:50-55